Showing 7251-7260 of 9298 results for "".
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://practicaldermatology.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- Bimekizumab Shows Durable Psoriasis Clearance and 3-Year HS Controlhttps://practicaldermatology.com/news/bimekizumab-shows-durable-psoriasis-clearance-and-3-year-hs-control/2486394/New analyses from the BE RADIANT and BE VIVID trials showed the durability of response with bimekizumab (Bimzelx; UCB) in treating plaque psoriasis, alongside positive long-term findings in hidradenitis suppurativa (HS). Resu
- Study: Tumor Location and Histologic Features Linked to Melanoma Recurrencehttps://practicaldermatology.com/news/study-tumor-location-and-histologic-features-linked-to-melanoma-recurrence/2485922/In patients with stage I–II melanoma, tumor location and histopathologic features were linked with recurrence risk beyond traditional factors such as ulceration and tumor thickness, according to a new study. Investigators exa
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://practicaldermatology.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev